文献速递胸部肿瘤

黏液组织学肺腺癌:临床、基因组和免疫微环境特征及其对免疫治疗和KRASG12C抑制剂的结局

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.
PubMed 文献 · Ann Oncol · 2024-12-03

这项多机构研究比较了4082例肺腺癌中9.9%的黏液组织学肺腺癌(LUADMuc)与无黏液组织学肺腺癌(LUADnon-muc)的临床、基因组、免疫表型和转录特征及治疗结局。LUADMuc具有更轻的吸烟史、更低PD-L1表达和肿瘤突变负荷,KRAS等突变富集,对免疫检查点抑制剂和化疗免疫治疗结局更差,对KRASG12C抑制剂ORR和PFS相似但OS更短。

要点

  • LUADMuc占肺腺癌9.9%,吸烟史更轻,PD-L1和TMB更低。
  • LUADMuc富集KRAS、NKX2-1、STK11、SMARCA4、GNAS突变和ALK重排。
  • 免疫检查点抑制剂治疗LUADMuc的ORR、PFS和OS均差于LUADnon-muc。

核心结论

  • LUADMuc是肺腺癌的独特亚群,具有独特的临床病理、基因组、免疫表型和转录特征,对标准免疫治疗为基础的方案结局更差。

研究设计与样本

  • 来自五个机构和癌症基因组图谱泛癌图谱的肺腺癌患者,分为LUADMuc和LUADnon-muc,比较临床病理、基因组、免疫表型、转录特征和治疗结局。

主要发现

  • 在4082例肺腺癌中,9.9%为LUADMuc。
  • LUADMuc vs LUADnon-muc:中位吸烟量15 vs 20包年(P=0.008),中位PD-L1肿瘤比例评分0% vs 5%(P<0.0001),中位肿瘤突变负荷6.8 vs 8.5突变/兆碱基(P<0.0001)。
  • LUADMuc富集KRAS、NKX2-1、STK11、SMARCA4、GNAS突变和ALK重排,LUADnon-muc富集TP53、EGFR、BRAF和MET突变。
  • IV期诊断时,LUADMuc vs LUADnon-muc:对侧肺转移55.2% vs 36.9%(P<0.0001),脑转移23.3% vs 41.9%(P<0.0001)。
  • 转移性病例接受免疫检查点抑制剂:LUADMuc(n=112)vs LUADnon-muc(n=1511),ORR 8.4% vs 25.9%(P<0.0001),中位PFS 2.6 vs 3.9个月(P<0.0001),中位OS 9.9 vs 17.2个月(P<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 10% of lung adenocarcinomas (LUADs) have mucinous histology (LUADMuc), which is associated with a light/absent smoking history and a high prevalence of KRAS mutations. We sought to characterize LUADMuc by comparing it with LUAD without mucinous histology (LUADnon-muc) and determine the relative benefit of current treatments. PATIENTS AND METHODS: Patients with LUAD from five institutions and The Cancer Genome Atlas Pan-Cancer Atlas classified as LUADMuc or LUADnon-muc were included. Clinicopathologic, genomic, immunophenotypic, transcriptional features, and treatment outcomes were compared between LUADMuc and LUADnon-muc. RESULTS: Of 4082 patients with LUAD, 9.9% had LUADMuc. Compared with LUADnon-muc, patients with LUADMuc had a lighter smoking history (median 15 versus 20 pack-years; P = 0.008), lower programmed death-ligand 1 (PD-L1) tumor proportion score (median 0% versus 5%, P < 0.0001), and lower tumor mutation burden (median 6.8 versus 8.5 mutations/megabase, P < 0.0001). Mutations in KRAS, NKX2-1 [thyroid transcription factor 1 (TTF-1)], STK11, SMARCA4, GNAS, and ALK rearrangements were enriched in LUADMuc, while TP53, EGFR, BRAF, and MET mutations were enriched in LUADnon-muc. At stage IV diagnosis, LUADMuc was more likely to have contralateral lung metastasis (55.2% versus 36.9%, P < 0.0001) and less likely to have brain metastases (23.3% versus 41.9%, P < 0.0001). Compared with LUADnon-muc, LUADMuc cases showed lower intratumor CD8+, PD-1+, CD8+PD-1+, and FOXP3+ cells. Among metastatic cases receiving immune checkpoint inhibitors, compared with LUADnon-muc (n = 1511), LUADMuc (n = 112) had a lower objective response rate (ORR 8.4% versus 25.9%, P < 0.0001), and shorter median progression-free survival (mPFS 2.6 versus 3.9 months, P < 0.0001) and overall survival (mOS 9.9 versus 17.2 months, P < 0.0001). Similarly, patients with LUADMuc had worse outcomes to chemoimmunotherapy. LUADMuc (n = 18) and LUADnon-muc (n = 150) had similar ORR (16.7% versus 34.9%, P = 0.12) and mPFS (4.6 versus 5.6 months, P = 0.17) to treatment with KRASG12C inhibitors, but LUADMuc had shorter mOS (6.8 versus 10.8 months, P = 0.018). CONCLUSIONS: LUADMuc represents a distinct LUAD subpopulation with unique clinicopathologic, genomic, immunophenotypic, and transcriptional features, achieving worse outcomes to standard immunotherapy-based treatments.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Di Federico A, Hong L, Elkrief A, et al. Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors. Ann Oncol. 2024. PMID: 39637943. doi:10.1016/j.annonc.2024.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。